ArticleMicroorganisms2024
Gut Microbiota and Biomarkers of Intestinal Barrier Damage in Cirrhosis.
Article in Microorganisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 39 citations in OpenAlex.
- The Crosstalk Role of Intestinal Barrier Damage in the Gut-Organ Axis and its Potential Therapeutic Implications.Current microbiology · 2026Review
- Human biomarker navigator.iMeta · 2026Review
- Diamine Oxidase and Gastrointestinal Diseases.Biomolecules · 2026Review
- Unique gut microbiota and metabolomic profiling as biomarker of post-transplant recovery in acute-on-chronic liver failure after liver transplantation.Applied microbiology and biotechnology · 2026Article
- Integrated Metabolomics and Microbial Profiling in Patients with Irritable Bowel Syndrome.Journal of microbiology and biotechnology · 2026Article
- Deciphering the gut microbiota's role in infection risk: Mendelian randomization analysis of microbial taxa and infectious outcomes.Frontiers in microbiology · 2026Article
- Gut microbiota profiles associated with persistent anal HPV infection in men who have sex with men.BMC infectious diseases · 2025Article
- Perioperative Oral Immunonutrient Regulation of Intestinal Barrier and Gut Microbiota in Patients with Gastric Cancer, a Randomized Controlled Clinical Trial.Biomedicines · 2025Article
- Relationship between gut microbiota dysbiosis and bile acid in patients with hepatitis B-induced cirrhosis.BMC gastroenterology · 2025Article
- Presepsin in Hepatic Pathology: Bridging the Gap in Early Sepsis Detection.Diagnostics (Basel, Switzerland) · 2025Review
- Oxidative Stress Model of Lipopolysaccharide-Challenge in Piglets of Wuzhishan Miniature Pig.Veterinary sciences · 2025Article
- Exercise Remodels Akkermansia-Associated Eicosanoid Metabolism to Alleviate Intestinal Senescence: Multi-Omics Insights.Microorganisms · 2025Article
- Integrated analysis of microbiome and transcriptome reveals the mechanisms underlying the chlorogenic acid-mediated attenuation of oxidative stress and systemic inflammatory responses via gut-liver axis in post-peaking laying hens.Journal of animal science and biotechnology · 2025Article
- Bacteroides, Metabolites, and Lymphocytes: A Triad of Biomarkers in Small Intestinal Bacterial Overgrowth.Food science & nutrition · 2025Article
- Article
- HIF-1α Enhances Intestinal Injury and Inflammation in Severe Acute Pancreatitis Through NLRP3 Inflammasome Activation.Digestive diseases and sciences · 2025Article
- Intestine-Decipher Engineered Capsules Protect Against Sepsis-induced Intestinal Injury via Broad-spectrum Anti-inflammation and Parthanatos Inhibition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Sodium Butyrate Inhibits Necroptosis by Regulating MLKL via E2F1 in Intestinal Epithelial Cells of Liver Cirrhosis.Journal of clinical and translational hepatology · 2025Article
- Gut microbiota in liver diseases: initiation, development and therapy.Frontiers in medicine · 2025Review
- Exploring the Therapeutic and Gut Microbiota-Modulating Effects of Qingreliangxuefang on IMQ-Induced Psoriasis.Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut dysbiosis and subclinical intestinal damage are common in cirrhosis. The aim of this study was to examine the association of intestinal damage biomarkers (diamine oxidase [DAO], claudin 3, and intestinal fatty acid binding protein [I-FABP; FABP2]) with the state of the gut microbiota in cirrhosis. The blood levels of DAO were inversely correlated with blood levels of claudin 3, lipopolysaccharide (LPS), presepsin, TNF-α, and the severity of cirrhosis according to Child-Pugh scores. The blood level of I-FABP was directly correlated with the blood level of claudin 3 but not with that of DAO. Patients with small intestinal bacterial overgrowth (SIBO) had lower DAO levels than patients without SIBO. There was no significant difference in claudin 3 levels and I-FABP detection rates between patients with and without SIBO. The DAO level was directly correlated with the abundance of Akkermansiaceae, Akkermansia, Allisonella, Clostridiaceae, Dialister, Lactobacillus, Muribaculaceae, Negativibacillus, Ruminococcus, Thiomicrospiraceae, Verrucomicrobiae, and Verrucomicrobiota; and it was inversely correlated with the abundance of Anaerostipes, Erysipelatoclostridium, and Vibrio. The I-FABP level was directly correlated with Anaerostipes, Bacteroidia, Bacteroidota, Bilophila, Megamonas, and Selenomonadaceae; and it was inversely correlated with the abundance of Brucella, Pseudomonadaceae, Pseudomonas, and Vibrionaceae. The claudin 3 level was directly correlated with Anaerostipes abundance and was inversely correlated with the abundance of Brucella, Coriobacteriia, Eggerthellaceae, and Lactobacillus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.